Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer

GU medical oncologist Dr. Rana McKay and urologist Dr. Neal Shore explore how predictive biomarkers and genetic testing are informing risk assessment and guiding personalized treatment decisions in clinical practice.

EP: 1.Metastatic Prostate Cancer: Background and Patient Prognosis

Now Viewing

EP: 2.Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer

EP: 3.Treatment Selection in Metastatic and Castration Resistant Prostate Cancer: Optimizing Outcomes and Preserving Patient Quality of Life

EP: 4.Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis

EP: 5.Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer

EP: 6.Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape

EP: 7.Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer

Related Videos

Related Content

Advertisement

April 17th 2025

Urologists perform first remote robot-assisted HIFU for prostate cancer

Hannah Clarke

“We are witnessing the dawn of teletreatment,” says Jihad Kaouk, MD, FACS.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

April 14th 2025

Study underway to assess 3-fraction SBRT regimen in prostate cancer

Hannah Clarke

"The goal of the PRECISION study is to ensure that treatment with 3 radiation doses does not lead to greater side effects than those observed in the PACE-B study," says Professor Duncan B. McLaren, MBBS.

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

April 7th 2025

Genetic test can predict risk of toxicity following radiation for prostate cancer

Hannah Clarke

"This finding reinforces PROSTOX ultra as a true measure of the biological response to radiation, independent of treatment era or technique that can identify the safest course of treatment to avoid toxicity," says Amar U. Kishan, MD.

April 7th 2025

What urologists can expect in Q2 of 2025

Hannah Clarke Benjamin P. Saylor

A lookahead of the notable FDA decisions and conferences slated for Q2 2025.

Related Content

Advertisement

April 17th 2025

Urologists perform first remote robot-assisted HIFU for prostate cancer

Hannah Clarke

“We are witnessing the dawn of teletreatment,” says Jihad Kaouk, MD, FACS.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

April 14th 2025

Study underway to assess 3-fraction SBRT regimen in prostate cancer

Hannah Clarke

"The goal of the PRECISION study is to ensure that treatment with 3 radiation doses does not lead to greater side effects than those observed in the PACE-B study," says Professor Duncan B. McLaren, MBBS.

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

April 7th 2025

Genetic test can predict risk of toxicity following radiation for prostate cancer

Hannah Clarke

"This finding reinforces PROSTOX ultra as a true measure of the biological response to radiation, independent of treatment era or technique that can identify the safest course of treatment to avoid toxicity," says Amar U. Kishan, MD.

April 7th 2025

What urologists can expect in Q2 of 2025

Hannah Clarke Benjamin P. Saylor

A lookahead of the notable FDA decisions and conferences slated for Q2 2025.